BACKGROUND: The aberrant activation of oncogenic signaling such as Ras/MAPK signaling is a frequent event in human cancers. In addition to genetic changes, epigenetic silencing of inhibitors in Ras/MAPK signaling contributes to the activation of Ras/MAPK signaling. Recently, ANXA6 has been shown to interact with Ras-GAP1 and inhibit Ras activation in human breast cancer. However, whether and how it is involved in human cancers remain unknown. METHODS: Real-time PCR was used to determine ANXA6 expression in gastric cancer cells and primary gastric carcinomas. Next, we explored the methylation of ANXA6 promoter in cell lines and tumor tissues with methylation-specific PCR and bisulfite genomic sequencing. We also investigated the function of ANXA6 in gastric cancer cells with colony formation assay and western blotting analysis. RESULTS: ANXA6 was down-regulated in gastric cancer cells and primary gastric carcinomas. Ectopic ANXA6 expression inhibited the growth of gastric cancer cells and the activity of Ras/MAPK signaling. Its expression was restored after pharmaceutical demethylation. ANXA6 promoter was methylated in gastric cancer cell lines (6/6) and primary gastric carcinoma tissues (29/156). Interestingly, the knockdown of oncoprotein Yin Yang 1 (YY1) also restored ANXA6 expression and promoted the demethylation of ANXA6 promoter. However, ANXA6 methylation was not associated with clinical parameters such as differentiation, and TNM staging. Neither Kaplan-Meier Curve nor Cox regression analysis revealed a significant role of ANXA methylation to predict the survival of gastric cancer patients. CONCLUSIONS: We firstly reported that ANXA6 is epigenetically silenced through promoter methylation in human cancers and YY1 is important to initiate or maintain ANXA6 promoter methylation in gastric cancer cells. ANXA6 functions as a tumor suppressor in gastric cancer cells through the inhibition of Ras/MAPK signaling. ANXA6 methylation is not a prognostic factor for gastric cancer patients.
BACKGROUND: The aberrant activation of oncogenic signaling such as Ras/MAPK signaling is a frequent event in humancancers. In addition to genetic changes, epigenetic silencing of inhibitors in Ras/MAPK signaling contributes to the activation of Ras/MAPK signaling. Recently, ANXA6 has been shown to interact with Ras-GAP1 and inhibit Ras activation in humanbreast cancer. However, whether and how it is involved in humancancers remain unknown. METHODS: Real-time PCR was used to determine ANXA6 expression in gastric cancer cells and primary gastric carcinomas. Next, we explored the methylation of ANXA6 promoter in cell lines and tumor tissues with methylation-specific PCR and bisulfite genomic sequencing. We also investigated the function of ANXA6 in gastric cancer cells with colony formation assay and western blotting analysis. RESULTS:ANXA6 was down-regulated in gastric cancer cells and primary gastric carcinomas. Ectopic ANXA6 expression inhibited the growth of gastric cancer cells and the activity of Ras/MAPK signaling. Its expression was restored after pharmaceutical demethylation. ANXA6 promoter was methylated in gastric cancer cell lines (6/6) and primary gastric carcinoma tissues (29/156). Interestingly, the knockdown of oncoprotein Yin Yang 1 (YY1) also restored ANXA6 expression and promoted the demethylation of ANXA6 promoter. However, ANXA6 methylation was not associated with clinical parameters such as differentiation, and TNM staging. Neither Kaplan-Meier Curve nor Cox regression analysis revealed a significant role of ANXA methylation to predict the survival of gastric cancerpatients. CONCLUSIONS: We firstly reported that ANXA6 is epigenetically silenced through promoter methylation in humancancers and YY1 is important to initiate or maintain ANXA6 promoter methylation in gastric cancer cells. ANXA6 functions as a tumor suppressor in gastric cancer cells through the inhibition of Ras/MAPK signaling. ANXA6 methylation is not a prognostic factor for gastric cancerpatients.
Authors: Liangjing Wang; Xian Wang; Xiaojia Wang; Pan Jie; Haiqi Lu; Shengjie Zhang; Xiaoying Lin; Emily Ky Lam; Yan Cui; Jun Yu; Hongchuan Jin Journal: Am J Cancer Res Date: 2010-11-10 Impact factor: 6.166
Authors: Ingrid G M Kolfschoten; Bart van Leeuwen; Katrien Berns; Jasper Mullenders; Roderick L Beijersbergen; Rene Bernards; P Mathijs Voorhoeve; Reuven Agami Journal: Cell Date: 2005-06-17 Impact factor: 41.582
Authors: S Vilá de Muga; P Timpson; L Cubells; R Evans; T E Hayes; C Rentero; A Hegemann; M Reverter; J Leschner; A Pol; F Tebar; R J Daly; C Enrich; T Grewal Journal: Oncogene Date: 2008-10-13 Impact factor: 9.867
Authors: Hongchuan Jin; Xian Wang; Jianming Ying; Ada H Y Wong; Yan Cui; Gopesh Srivastava; Zhong-Ying Shen; En-Min Li; Qian Zhang; Jie Jin; Sabine Kupzig; Anthony T C Chan; Peter J Cullen; Qian Tao Journal: Proc Natl Acad Sci U S A Date: 2007-07-18 Impact factor: 11.205
Authors: Elisabeth M Meier; Lisa Rein-Fischboeck; Rebekka Pohl; Josef Wanninger; Andrew J Hoy; Thomas Grewal; Kristina Eisinger; Sabrina Krautbauer; Gerhard Liebisch; Thomas S Weiss; Christa Buechler Journal: Mol Cell Biochem Date: 2016-06-23 Impact factor: 3.396
Authors: Huang Kie Kyon; Arnoud Boot; Nisha Padmanabhan; Kevin Lim; Supriya Srivastava; Shuwen Chen; Zhiyuan Wu; Hyung-Ok Lee; Vineeth T Mukundan; Charlene Chan; Yarn Kit Chan; Ong Xuewen; Jason J Pitt; Zul Fazreen Adam Isa; Manjie Xing; Ming Hui Lee; Angie Lay Keng Tan; Shamaine Ho Wei Ting; Micah A Luftig; Dennis Kappei; Warren D Kruger; Jinsong Bian; Ying Swan Ho; Ming Teh; Steve George Rozen; Patrick Tan Journal: Genome Biol Date: 2021-06-01 Impact factor: 13.583
Authors: Dermot O'Sullivan; Paul Dowling; Helena Joyce; Edel McAuley; Andrew McCann; Michael Henry; Brianan McGovern; Paul Barham; Fergal C Kelleher; Jean Murphy; Susan Kennedy; Niall Swan; Michael Moriarty; Martin Clynes; Annemarie Larkin Journal: Br J Cancer Date: 2017-09-07 Impact factor: 7.640